NCT06785636 2026-04-22
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT05413850 2026-04-13
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
NCT06190899 2026-04-13
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
Phase 1/2 Recruiting
NCT07103018 2026-03-23
STRIKE-001
K36 Therapeutics, Inc.
Phase 1 Recruiting
NCT07130708 2025-08-19
Exploring the Potential of Robotic Telesurgery in Remote Settings
AdventHealth
Phase NA Recruiting
NCT05574647 2025-07-24
IP7-PACIFIC
Imperial College London
Phase NA Recruiting
NCT04597411 2025-03-21
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Phase 1 Recruiting
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting
NCT06582628 2024-12-02
TEAM PC
Fundacion Oncosur
Phase 2 Recruiting
NCT06706921 2024-11-27
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
Phase 4 Recruiting
NCT06636747 2024-10-15
High Resolution Diffusion Weighted Imaging in Prostate
The First Affiliated Hospital with Nanjing Medical University
Recruiting